Journey Medical Corporation (DERM) announced that the Company has submitted a New Drug Application to the FDA seeking approval for DFD-29 for the treatment of inflammatory lesions and erythema of rosacea in adults. DFD-29 is being developed in collaboration with Dr. Reddy’s Laboratories (RDY). “This NDA submission is a significant milestone for Journey Medical and we look forward to collaborating with the FDA during its review to bring DFD-29, a potentially differentiated, best-in-class oral rosacea treatment, one step closer to patients. Based on the data seen in our pivotal trials, DFD-29 could fundamentally improve the treatment paradigm for patients suffering from both inflammatory lesions and erythema from rosacea,” said Claude Maraoui, Co-Founder, President and Chief Executive Officer of Journey Medical. The NDA submission is supported by positive data from Journey Medical’s two DFD-29 Phase 3 clinical trials for the treatment of rosacea.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DERM:
- Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million
- Journey Medical Corp trading resumes
- Journey Medical Corp trading halted, volatility trading pause
- Journey Medical price target raised to $8 from $6 at B. Riley
- Journey Medical announces completion of pre-NDA meeting with FDA for DFD-29